Erratum: Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment (Clinical and Translational Oncology (2001) 12 (22-26) DOI:10.1007/s12094-010-0462-3);Contribution of hypoxia-measuring molecular imaging techniques to radiotherapy planning and treatment

Clinical and Translational Oncology

Volumn 12, Issue 1, 2010, Pages 22-26

  Ferrer Albiach, Carlos ^a   Conde Moreno, Antonio ^a   Rodríguez Cordón, Marta ^a   Morillo MacÍas, Virginia ^a   Bouché Babiloni, Ana ^a   Beato Tortajada, Inmaculada ^a   Sánchez Iglesias, Ángel ^a   Francés Muñoz, Alicia ^a  

^a Servicio de Oncología Radioterápica   (Spain)

Author keywords

Hypoxia; Molecular imaging; Radiotherapy

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 NITROIMIDAZOLE; CARBONATE DEHYDRATASE IX; DEOXYHEMOGLOBIN; FLUORODEOXYGLUCOSE; GLUCOSE TRANSPORTER 1; HEXAFLUOROBENZENE; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RADIOPHARMACEUTICAL AGENT; TIRAPAZAMINE; VASCULOTROPIN;

CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ELECTRON SPIN RESONANCE; GENE EXPRESSION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN TENSION; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SURVIVAL RATE; TISSUE OXYGENATION; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR HYPOXIA;

EID: 76049100453     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/S12094-010-0483-y     Document Type: Erratum

References (40)

1. S.M. Evans K.L. Du A.A. Chalian, et al. 2007 Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome Int J Radiat Oncol Biol Phys 69 1024 1031 17967299
2. P. Vaupel A. Mayer 2007 Hypoxia in cancer: significance impact on clinical outcome Cancer Metastasis Rev 26 225 239 10.1007/s10555-007-9055-1 1:CAS:528:DC%2BD2sXotFWrtLo%3D 17440684
3. B. Gagel M. Piroth M. Pinkawa, et al. 2007 pO polarography contrast enhanced color duplex sonography (18-F) fluoromisonidazole and (18-F) fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy relevant tumor oxygenation for only bricks in the puzzle of tumor hypoxia BMC Cancer 7 113 10.1186/1471-2407-7-113 17598907 (Pubitemid 47272139)
4. J.G. Rajendran K. Hendrickson A. Spence, et al. 2006 Hypoxia imaging directed radiation treatment planning Eur J Med Mol Imaging 33 S44 S53 10.1007/s00259-006-0135-1
5. J.L. Tatum G.J. Kellof R.J. Gillies, et al. 2006 Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy Int J Radiat Biol 82 699 757 10.1080/09553000601002324 1:CAS:528:DC%2BD28XhtlejsbnM 17118889 (Pubitemid 44832019)
6. A. Mayer M. Hockel A. Wree, et al. 2008 Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia Cancer Res 68 4719 4726 10.1158/0008-5472.CAN-07-6339 1:CAS:528:DC%2BD1cXnt1aqu7o%3D 18559518
7. M. Nordmark J. Grau V. Gebski, et al. 2007 Differential risk assessments from five hypoxia specific assay: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients Radiother Oncol 83 389 397 10.1016/j.radonc.2007.04.021 (Pubitemid 46907981)
8. M. Bache R. Rederman H. Said, et al. 2006 Immunohistochemical detection of osteopontin in advanced head and neck cancer: prognostic role and correlation with oxygen electrode measurements hypoxia inducible factor 1-α related markers and hemoglobin levels Int J Radiat Oncol Biol Phys 66 1481 1487 1:CAS:528:DC%2BD28Xht1ClsrbK 17056190
9. A. Mayer M. Hockel P. Vaupel 2006 Endogenous hypoxia markers in locally advanced of the uterine cervix: reality or wishful thinking? Strahlenter Onkol 182 501 510 10.1007/s00066-006-1525-9 (Pubitemid 44316238)
10. B. Krause R. Beck M. Solvatzzoglou M. Piert 2006 Pet and PET/CT studies of tumor tissue oxygenation Q J Nucl Med Mol Imaging 50 28 45 1:STN:280:DC%2BD287mvVSgtQ%3D%3D 16557202
11. S.M. Evans K.L. Du A.A. Chalian, et al. 2007 Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome Int J Radiat Oncol Biol Phys 69 1024 1031 17967299
12. R.H. Mannan V.V. Somayaji J. Lee, et al. 1991 Radioiodinated 1-(5-iodo-5-deoxy-beta-Darabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia J Nucl Med 32 1764 1770 1:CAS:528:DyaK38Xhslyhsw%3D%3D 1880579
13. J. Saitoh H. Sakurai Y. Suzuki, et al. 2002 Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by beta-D-iodinated azomycin galactopyranoside (beta-D-IAZGP), and radiation sensitivity Int J Radiat Oncol Biol Phys 54 903 909 1:CAS:528:DC%2BD38Xns1Sit7o%3D 12377344
14. T. Grönroos L. Bentzen P. Marjamäki, et al. 2004 Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma Eur J Nucl Med Mol Imaging 31 513 520 10.1007/s00259-003-1404-x 14722675
15. H. Barthel H. Wilson D.R. Collingridge, et al. 2004 In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography Br J Cancer 90 2232 2242 1:CAS:528:DC%2BD2cXkt1Gnsb4%3D 15150578
16. L.S. Ziemer S.M. Evans A.V. Kachur, et al. 2003 Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5 Eur J Nucl Med Mol Imaging 30 259 266 1:CAS:528:DC%2BD3sXms1CntQ%3D%3D 12552344
17. J.A. O'Donoghue P. Zanzonico A. Pugachev, et al. 2005 Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl- bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models Int J Radiat Oncol Biol Phys 61 1493 1502 15817355
18. S.M. Evans A.V. Kachur C.Y. Shiue, et al. 2000 Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1 J Nucl Med 41 327 336 1:CAS:528:DC%2BD3cXhtlGnt74%3D 10688119
19. B. Gallez C. Baudelet B. Jordan 2004 Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications NMR Biomed 17 240 262 10.1002/nbm.900 1:CAS:528:DC%2BD2cXptFSmsL0%3D 15366026 (Pubitemid 39268771)
20. H. Huagang N. Khan J. O'Hara, et al. 2004 Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation I murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study Int J Radiat Oncol Biol Phys 59 834 843
21. C. Delmaire A. Krsinik V. Lethuc, et al. 2007 IRM fonctionelle cerebrale: bases prysiologiques, techniques at applications cliniques J Radiol 88 497 507 10.1016/S0221-0363(07)89849-0 1:STN:280:DC%2BD2s3kvVeltQ%3D%3D 17457260 (Pubitemid 46596317)
22. B. Krause B. Beck M. Souvatzouglou M. Piert 2006 PET and PET/CT studies of tumor tissue oxygenation Q J. Med Mol Imaging 50 28 43 1:STN:280: DC%2BD287mvVSgtQ%3D%3D
23. S.H. Yeh R.S. Liu L.C. Wu, et al. 1996 Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma Eur J Nucl Med 23 1378 1383 10.1007/BF01367595 1:STN:280: DyaK28zns1Ghsw%3D%3D 8781144 (Pubitemid 26340592)
24. B. Gagel P. Reinartz E. Dimartino, et al. 2004 pO(2) polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18) F]-2-fluoro-2′-deoxyglucose) An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 180 616 622
25. K. Lehtiö O. Eskola T. Viljanen, et al. 2004 Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer Int J Radiat Oncol Biol Phys 59 971 982 10.1016/j.ijrobp.2003.12.014 15234030 (Pubitemid 38834289)
26. R. Hicks D. Rischin R. Fisher, et al. 2005 Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia targeting chemotherapy agent Eur J Nucl Med Mol Imaging 32 1384 1391 10.1007/s00259-005-1880-2 16133382 (Pubitemid 41746841)
27. S.M. Eschmann F. Paulsen M. Reimold, et al. 2005 Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy J Nucl Med 46 253 260 15695784
28. M. Cherk S. Foo A. Poon, et al. 2006 Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non small cell lung cancer assessed by 18-F-Misonidazole and 18 F-FDG PET J Nucl Med 47 1921 1926 1:CAS:528:DC%2BD2sXksFKhtA%3D%3D 17138734
29. M. Yao M. Graham T. Hoffman, et al. 2004 The role of post-radiation therapy FDG-PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head and neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 99 1001 1010 10.1016/j.ijrobp.2004.01.040 (Pubitemid 38834292)
30. S. Eschmann F. Paulsen C. Bedeshem, et al. 2007 Hypoxia imaging 18-Fmisonidazole and PET: changes of kinetics during radiotherapy of head and neck cancer Radiother Oncol 83 406 410 10.1016/j.radonc.2007.05.014 1:CAS:528:DC%2BD2sXmsFKhtr8%3D 17543402 (Pubitemid 46915551)
31. D. Rischin R. Hicks R. Fisher, et al. 2006 Prognostic significance of 18-Fmisonidazole PET detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a sub-study of Trans Tasman Oncology group study 98.02 J Clin Oncol 24 2098 2104 10.1200/JCO.2005.05.2878 16648512 (Pubitemid 46622121)
32. N.Y. Lee J.G. Mechalakos S. Nehmeh, et al. 2008 Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study 70 2 13 1:CAS:528:DC%2BD2sXhsVentrzN
33. C. Wong J. Schmidt J. Bong, et al. 2006 Correlating metabolic and anatomic responses of primary lung cancers to radiotherapy by combined F-18 FDG PET/CT imaging Radiat Oncol 2 1 6
34. W.J. Koh K.S. Bergman J.S. Rasey, et al. 1995 Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography Int J Radiat Oncol Biol Phys 33 391 398 1:STN:280:DyaK2Mvgtlajug%3D%3D 7673026
35. N. Shu-Hang T. Yen J. Tung, et al. 2006 Prospective study of 18-FDG fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpable negative neck J Clin Oncol 24 4371 4376 10.1200/JCO.2006.05.7349 (Pubitemid 46646246)
36. P. Ahn M. Garg 2008 Positron emission tomography/computed tomography for target delineation in head and neck cancers Semin Nucl Med 38 141 148 10.1053/j.semnuclmed.2007.11.002 18243850 (Pubitemid 351163195)
37. J.F. Daisne T. Duprez B. Weynard 2004 Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison to CT, MR imaging and FDG/PET and validation with surgical specimen Radiology 233 93 100 10.1148/radiol.2331030660 15317953 (Pubitemid 39280962)
38. D. Wang C.J. Schultz P.A. Jursing, et al. 2006 Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma Int J Radiat Oncol Biol Phys 65 143 151 16618577
39. K. Khron J. Link R. Mason 2008 Molecular imaging of hypoxia J Nucl Med 49 [Suppl2] 129 148
40. Søvik E. Malinen D.R. Olsen 2009 Strategies for biologic image-guided dose escalation: a review Int J Radiat Oncol Biol Phys 73 650 658 19215819